FDA 发布 Q11 原料药开发与生产问答最终指南
Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)—Questions and Answers
FDA 发布 Q11 原料药开发与生产问答最终指南，文件编号为 FDA-2011-D-0436。该文件由 CDER 与 CBER 发布，就化学实体及生物技术/生物实体原料药起始物料的选择与论证提供澄清。文中说明可就任何指南随时提交评论。
该最终版问答由 CDER 与 CBER 发布，针对原料药起始物料的选择与论证提供澄清，并说明可随时提交评论。
GUIDANCE DOCUMENT
Final
- Docket Number:
- FDA-2011-D-0436
- Issued by:
-
Guidance Issuing Office
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research
Since the ICH guidance Q11 Development and Manufacture of Drug Substances (ICH Q11) was finalized, worldwide experience with implementation of the recommendations on the development and manufacture of drug substances has given rise to requests for clarification relating to the selection and justification of starting materials.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2011-D-0436.
来源：FDA Pharmaceutical Quality Documents · fda.gov